Oncology News | pharmaphorum

News

FDA clears Gamida’s cord blood therapy for cancer patients

The FDA has approved a stem cell-based therapy for cancer patients from Israeli biotech Gamida Cell that is designed to help them recover more quickly from aggressive chem

News

Merck, Moderna cue up phase 3 trials for mRNA cancer shot

Moderna and partner Merck & Co have fleshed out the data from their clinical trial of personalised mRNA vaccine for melanoma, saying the results support the start of a

News

Scheme aims to boost equity in digital cancer resources

Telehealth company Equiva has started working with cancer charity Gilda’s Club to make it easier for households affected by cancer in Minnesota to access online support re

News

More claudin buzz as Alentis raises $105m

Swiss biotech Alentis Therapeutics has raised a very respectable $105 million in third-round financing that will be dedicated to the development of its Claudin-targeting d

News

Phase 3 setbacks mar Eisai, Merck’s cancer alliance

Two late-stage trials combining Merck & Co’s cancer immunotherapy Keytruda with Eisai’s targeted cancer drug Lenvima have generated disappointing results in hard-to-tr

News

Lynparza gets OK for use in prostate, breast cancers on NHS

AstraZeneca and Merck & Co’s Lynparza will be made available to prostate and breast cancer patients in England and Wales, after cost-effectiveness assessor NICE backed

FDA clears Gamida’s cord blood therapy for cancer patients

Merck, Moderna cue up phase 3 trials for mRNA cancer shot

Scheme aims to boost equity in digital cancer resources

More claudin buzz as Alentis raises $105m

Phase 3 setbacks mar Eisai, Merck’s cancer alliance

Lynparza gets OK for use in prostate, breast cancers on NHS

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks